157924-46-4Relevant articles and documents
HETEROCYCLIC COMPOUND
-
Paragraph 0976; 0977, (2019/06/17)
Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
A convenient synthesis of N,N'-dibenzyl-2,4-diaminopyrimidine-2'- deoxyribonucleoside and 1-Methyl-2'-deoxypseudoisocytidine
Wellington, Kevin W.,Ooi, Hua Chee,Benner, Steven A.
experimental part, p. 275 - 291 (2009/12/26)
The syntheses of N,N'-dibenzyl-2,4-diaminopyrimidine-2'-deoxyribonucleoside and 1-methyl-2'-deoxypseudoisocytidine via Heck coupling are described. A survey of the attempts to use the Heck coupling to synthesize N,N'-dibenzyl-2,4-diaminopyrimidine-2'-deox
Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis
Pelphrey, Phillip M.,Popov, Veljko M.,Joska, Tammy M.,Beierlein, Jennifer M.,Bolstad, Erin S. D.,Fillingham, Yale A.,Wright, Dennis L.,Anderson, Amy C.
, p. 940 - 950 (2007/10/03)
The search for effective therapeutics for cryptosporidiosis and toxoplasmosis has led to the discovery of novel inhibitors of dihydrofolate reductase (DHFR) that possess high ligand efficiency: compounds with high potency and low molecular weight. Detaile